Sponsor Pipeline

Definium Therapeutics US, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
4
Phase 3
2
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-31 NCT06941844
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
Trial sites reduced: 25 -> 22 locations
2026-07-30 NCT07592689
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Trial sites expanded: 27 -> 32 locations
Active Trials by Phase
Phase 3
4
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07592689 A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) Major Depressive Disorder Recruiting
NCT06741228 A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) Generalized Anxiety Disorder Active, Not Recruiting
NCT06809595 A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) Generalized Anxiety Disorder Active, Not Recruiting
NCT06941844 A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) Major Depressive Disorder Active, Not Recruiting
Phase 2
NCT07303907 A Phase 2A Trial of DT402 for Autism Spectrum Disorder Autism Spectrum Disorder Recruiting
Disease Areas
Get alerts when Definium Therapeutics US, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free